Prognostic significance of epidermal growth factor-like domain 7 in pancreatic cancer

BACKGROUND： Recent studies have shown the clinical significance of epidermal growth factor-like domain 7（EGFL7）in a variety of cancers. However, the relationship between EGFL7 and the prognosis of pancreatic cancer（PC） remains unclear. The present study was undertaken to investigate the role of EGFL7 in the prognosis of PC.METHODS： The expression of EGFL7 in nine PC cell lines was first determined by Western blotting analysis. Tissue microarray-based immunohistochemical staining was performed in paired formalin-fixed paraffin-embedded tumor and non-tumor samples from 83 patients with PC. Finally,correlations between EGFL7 expression and clinicopathological variables as well as overall survival were evaluated.RESULTS： EGFL7 was widely expressed in all PC cell lines tested.EGFL7 expression in tumor tissues was significantly higher than that in non-tumor tissues（P0.040）. In addition, univariate analysis revealed that high EGFL7 expression in tumor tissues was significantly associated with poor overall survival,accompanied by several conventional clinicopathological variables, such as gender, histological grade and lymph node metastasis. In a multivariate Cox regression test, EGFL7 expression was identified as an independent marker for longterm outcome of PC.CONCLUSION： Our data showed that EGFL7 is extensively expressed in PC and that EGFL7 is associated with poor prognosis.

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy

Aim:Neoadjuvant chemotherapy may represent a shift in the treatment of locally advanced colon cancer.The angiogenic couple has-microRNA-126(miRNA-126)and epidermal growth factor-like domain 7(EGFL7)are transcribed from the same gene and regulates all aspects of angiogenesis and may influence the ability of tumor cells to disseminate.The aim was to analyze the relationship between miRNA-126 and EGFL7 and disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.Methods:This study included 71 patients from a phase II study all planned for three cycles of capecitabine and oxaliplatin before surgery.Blood was sampled at baseline and right before and after the operation.Circulating miRNA-126 was analysed by RT-qPCR and a quantitative immunoassay was used for the analyses of EGFL7.Results:The rates of 5-year disease-free survival(DFS)and overall survival(OS)were 80%and 85%,respectively.The level of circulating miRNA-126 before the operation predicts recurrence,P=0.035.In patients with values below and above the median the recurrence rate was 31%and 4%,respectively.Similar results applied to EGFL7.A combined estimate identified a subgroup of patients(25 of 71)with no recurrence and a 5-year DFS and OS rate of 100%,respectively.Conclusion:MicroRNA-126 and EGFL7 are predictors for disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy and may assist in selection of adjuvant chemotherapy.

OPN、EGFL 7在乳腺癌患者癌组织中的表达及临床意义

目的探讨骨桥蛋白(OPN)、表皮生长因子样结构域-7(EGFL7)在乳腺癌患者癌组织中的表达及临床意义。方法选取2019年1月至2020年12月期间于濮阳市安阳地区医院接受诊疗的82例乳腺癌患者为研究对象,观察所有入选者临床病理特征,分析不同病理特征乳腺癌患者癌组织中OPN、EGFL7表达及临床意义。结果TNM分期为Ⅲ~Ⅳ期、发生淋巴结转移的乳腺癌患者癌组织中OPN阳性表达率高于TNM分期为Ⅰ~Ⅱ期、未发生淋巴结转移的乳腺癌患者(P<0.05);TNM分期为Ⅲ~Ⅳ期、发生淋巴结转移的乳腺癌患者癌组织中EGFL7阳性表达率高于TNM分期为Ⅰ~Ⅱ期、未发生淋巴结转移的乳腺癌患者(P<0.05)。结论OPN、EGFL7可能参与乳腺癌疾病进展,与乳腺癌TNM分期、淋巴结转移密切相关。

miR-126靶向EGFL7抑制乳腺癌细胞MDA-MB-231上皮-间质转化

目的:探讨表皮生长因子样结构域7(epidermal growth factor-like domain 7,EGFL7)参与肿瘤细胞侵袭的可能分子机制。方法:设计构建miR-126过表达质粒,将该质粒转染并筛选培养乳腺癌细胞MDA-MB-231,Western印迹法检测EGFL7,Wnt-1,β-catenin,E-cadherin蛋白的表达变化,免疫组织化学检测Vimentin蛋白的表达并观察细胞形态变化,RT-PCR检测Twist和Slug转录因子mRNA表达,Transwell小室体外侵袭实验观察肿瘤细胞的体外侵袭能力。结果:成功建立过表达mi R-126的转染乳腺癌细胞株MDA-MB-231/miR-126,稳定转染细胞株EGFL7蛋白表达下调(P<0.01),并下调Wnt-1/β-catenin蛋白水平(P=0.02/P<0.01),E-cadherin蛋白表达上调(P<0.01),Vimentin蛋白表达下调,且细胞形态由梭形间充质样向多边形上皮样转化;Twist和Slug转录因子表达下调(P<0.01),肿瘤细胞体外侵袭能力减弱(P<0.01)。结论:miR-126通过靶向调节EGFL7调控Wnt-1/β-catenin信号通路及Twist,Slug转录因子,抑制乳腺癌细胞MDA-MB-231上皮-间质转化(epithelialmesenchymaltransition,EMT),降低了乳腺癌细胞MDA-MB-231体外侵袭能力,EGFL7可作为一种预测乳腺癌转移的重要生物标志物,并可能成为一种潜在的治疗靶点。